At a glance
- Originator Kotobuki Seiyaku
- Class Antigouts; Small molecules; Uricosurics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 23 Mar 2007 Discontinued - Phase-II for Gout in Japan (PO)
- 18 Mar 2001 Phase-II clinical trials for Gout in Japan (PO)
- 20 Oct 1994 Phase-I clinical trials for Gout in Japan (PO)